Skip to main content
SpringerLink
Log in

Naloxone increases bioactive LH in man: evidence for selective release of early LH pool

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Opioid peptides inhibit LH secretion and the opiate antagonist naloxone provokes increases in plasma LH levels by release of endogenous GnRH from the hypothalamus. To explore the effect of endogenously released GnRH on the mobilization of bioactive LH pools, the bioactive LH response to a single iv bolus dose of 20 mg naloxone has been evaluated and compared to the immunoactive pattern of the hormone in eight young normal male volunteers. Blood samples were withdrawn at 15, 30, 45, 60, 90, 120 min after naloxone injection and LH levels were measured by RIA and rat interstitial cell testosterone (RICT) bioassay. A significant increase in both bio and immuno active LH was observed in all subjects after 15–30 min (p < 0.05 to p < 0.001), reaching maximal levels at 30–60 min for both forms of the hormone. The time course of the bioactive LH response magnified the immunoactive LH pattern, and the maximum fold increases were 1.4 and 1.3 fold (62.4 ± 5.5 SE and 25.0 ± 3.7 SE mlU/ml) from basal bio and immuno LH levels of 25.9 ± 4.3 SE and 11.1 ± 2.0 SE mlU/ml respectively. An early single peak response of bio and immunoactive LH was observed in six subjects while a biphasic pattern was observed in two subjects with a clearly defined and prominent early pool followed by a second pool of higher magnitude. Both bio and iummunoactive LH levels began to decline at 45–60 min, but in most subjects remained significantly elevated by about 30% above the basal values at 120 min. The finding of a significant early bioactive LH increase gives further support to the clinical use of naloxone as a test to investigate the hypothalamic function in man.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bruni J.F., Van Vugt S., Marshall S., Meites J. Effect of naloxone, morphine and methionine enkephalin on serum prolactin, Iuteinizing hormone, follicle stimu: Itating hormone and growth hormone. Life Sci. 21: 461, 1977.

    Article  PubMed  CAS  Google Scholar 

  2. Meites J., Bruni J.F., Van Vugt D.A., Smith A.F. Mini-review: relation of endogenous opioid peptides and morphine to neuroendocrine function. Life Sci. 24:1325, 1979.

    Article  PubMed  CAS  Google Scholar 

  3. Cicero T.J., Shainker B.A., Meyer E.R. Endogenous opioids participate in the regulation of the hypothalamic-pituitary-Iuteinizing hormone axis and testosterone’s negative feedback control of luteinizing hormone. Endocrinology 104:1286, 1979.

    Article  PubMed  CAS  Google Scholar 

  4. Blank M.S., Panerai A.E., Friesen H.G. Opioid peptides modulate luteinizing hormone secretion during sexual maturation. Science 203:1129, 1979.

    Article  PubMed  CAS  Google Scholar 

  5. Stubbs W.A., Jones A., Edward C.R.W., Delitala G., Jeffcoate W.J., Ratter S.J., Besser G.M., Bloom S.R., Alberti K.G.M.M. Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet 2:1125, 1978.

    Google Scholar 

  6. Quigley M.E., Yen S.S.C. The role of endogenous opiates on LH secretion during the menstrual cycle. J. Clin. Endocrinol. Metab. 51:179, 1980.

    Article  PubMed  CAS  Google Scholar 

  7. Morley J.E., Baranetsky N.G., Wingert T.D., Carlson H.E., Hershman J.M., Melmed S., Levin S.R., Jamison K.R., Weitzman R., Chang R.J., Varner A.A. Endocrine effects of naloxone-induced opiate receptor blockade. J. Clin. Endocrinol. Metab. 50: 251, 1980.

    Article  PubMed  CAS  Google Scholar 

  8. Grossman A., Moult B.J., Gaillard R.C., Delitala G., Toff W.D., Rees L, Besser G.M. The opioid control of LH and FSH release: effects of a metenkephalin analogue and naloxone. Clin. Endocrinol. 74:41, 1981.

    Article  Google Scholar 

  9. Veldhuis J.D., Worgul T.J., Mousaert R., Hammond J.M.. A possible role for endogenous opioids in the control of prolactin and Iuteinizing-hormone secretion in the hu man. J. Endocrinol. Invest. 4: 31, 1981.

    Article  PubMed  CAS  Google Scholar 

  10. Delitala G., Devilla L, Arata L. Opiate receptors and anterior pituitary hormone secretion in man. Effect of naloxone infusion. Acta Endocrinol. (Kbh). 97:150, 1981.

    CAS  Google Scholar 

  11. Fraioli F., Panerai A.E., Santoro C., Fabbri A., Santoro F., Isidori A. Control of gonadotropin secretion in man: role of opioid peptides. Horm. Metab. Res. 16: 312, 1982.

    Article  Google Scholar 

  12. Ellingboe J., Veldhuis J.D., Mendelsohn J.H., Kvenle J.C, Mello N.K. Effect of endogenous opioid blockade on the amplitude and frequency of pulsatile luteinizing hormone secretion in normal man. J. Clin. Endocrinol. Metab. 59: 854, 1984.

    Google Scholar 

  13. Rotsztejn W.H., Drouva S.V., Pattou E., Kordon C. Met-enkephalin inhibits in vitro dopamine-induced LH-RH release from mediobasal hypothalamus of male rats. Nature 274: 281, 1978.

    Article  PubMed  CAS  Google Scholar 

  14. Cicero T.J., Meyer E.R., Bell R.D., Koch G.A. Effects of morphine and methadone on serum testosterone and luteinizing hormone levels and on the secondary sex organs of the male rat. Endocrinology 98: 367, 1976.

    Article  PubMed  CAS  Google Scholar 

  15. Cicero T.J., Bell R.D., Meyer E.R., Schweitzer J. Narcotics and the hypothalamic-pituitary-gonadal axis: acute effects on luteinizing hormone, testosterone and androgen-dependent systems. J. Pharmacol. Exp. Ther. 201: 76, 1977.

    PubMed  CAS  Google Scholar 

  16. Mirin S.M., Mendelsohn J.H., Ellingboe J., Meyer R.E. Acute effects of heroin and naltrexone on testosterone and gonadotropin secretion: a pilot study. Psychoneuroendocrinology: 1: 359, 1976.

    Article  Google Scholar 

  17. Pang C.N., Zimmermann E., Sawyer C.H. Morphine inhibition of the preovulatory surges of plasma luteinizing hormone and follicle-stimulating hormone in the rat. Endocrinology 101: 726, 1977.

    Article  Google Scholar 

  18. Cicero T.J., Badger T.M., Wilcox C.E., Bell R.D., Meyer E.R. Morphine decreases luteinizing hormone by an action on the hypothalamic pituitary axis. J. Pharmacol. Exp. Ther. 203: 548, 1977.

    PubMed  CAS  Google Scholar 

  19. Cicero T.J., Wilcox C.E., Bell R.D., Meyer E.R. Acute reduction in serum testosterone levels by narcotics in the male rat: stereo-specificity, blockade by naloxone and tolerance. J. Pharmacol. Exp. Ther. 198: 340, 1976.

    PubMed  CAS  Google Scholar 

  20. Veldhuis J.D., Rogol A.D., Johnson M.L, Dufau M.L. Endogenous opiates modulate the pulsatile secretion of biologically active luteinizing hormone in man. J.Clin. Invest. 72:2031, 1983.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  21. Beitins I.Z., Dufau M.L, O’Loughlin K., Catt K.J., Mc Arthur J.W. Analysis of biological and immunological activities in the two pools of LH released during constant infusion of luteinizing hormone releasing hormone (LH-RH) in men. J. Clin. Endocrinol. Metab. 65: 605, 1977.

    Article  Google Scholar 

  22. Marrama P., Zaidi A.A., Montanini V., Celani M.F., Cioni K., Carani C., Morabito F., Resentini M., Bonati B., Baraghini G.F. Age and sex related variations in biologically active and immunoreactive serum luteinizing hormone. J. Endocrinol. Invest. 6: 427, 1983.

    Article  PubMed  CAS  Google Scholar 

  23. Dufau M.L, Pock R., Neubauer A., Catt K.J. In vitro bioassay of LH in human serum: the rat interstitial cell testosterone (RICT) assay. J. Clin. Endocrinol. Metab. 42: 958, 1976.

    Article  PubMed  CAS  Google Scholar 

  24. Gnessi L, Ferraris L., Ferretti R., Fabbri A., Moretti C., Bonifacio V., Isidori A., Fraioli F. In vitro bioassay of LH: some methodological aspects. J. Endocrinol. Invest. 7 (Suppl. 3): 33, 1984.

    PubMed  Google Scholar 

  25. Fraioli F., Isidori A. Sistemi a radioligandi in endocrinologia. Società Editrice Universo (SEU), Roma, 1977.

    Google Scholar 

  26. Rodbard D. Statistical quality control and routine data processing for RIA and immunoradiometric assays. Clin. Chem. 20:1255, 1974.

    PubMed  CAS  Google Scholar 

  27. Steel R.G.D., Torrie J.H. Principles and procedures of statistics. Mc Graw-Hill, New York, 1960.

    Google Scholar 

  28. Berkowitz B.A., Ngai S.H., Hampstead J., Spector S. Disposition of naloxone. Use of a new radioimmunoas say. J. Pharmacol. Exp. Ther. 195: 493, 1975.

    Google Scholar 

  29. Dufau M.L, Beitins I.Z., Mc Arthur J.W., Catt K.J. Effects of luteinizing hormone releasing hormone (LHRH) upon bioactive and immuno-active serum LH levels in normal subjects. J. Clin. Endocrinol. Metab. 43: 658, 1976.

    Article  PubMed  CAS  Google Scholar 

  30. Cicero T.J., Wilcox CE., Bell R.D., Meyer E.R. Naloxone induced increase in serum luteinizing hor mone in the male: mechanisms of action. J. Pharmacol. Exp. Ther. 212: 573, 1980.

    PubMed  CAS  Google Scholar 

  31. Wilkes H.H., Yen S.S.C. Augmentation by naloxone of efflux of LRF from super-fused medial basal hypothalamus. Life Sci. 28:2355, 1980.

    Article  Google Scholar 

  32. Blanks M.S., Roberts D.L. Antagonist of gonadotropin-releasing hormone blocks naloxone-induced elevations in serum luteinizing hormone. Neuroendocrinology 33: 309, 1982.

    Article  Google Scholar 

  33. Law P.Y., Loh H.H. 3H-Leu5-enkephalin specific binding to synaptic membrane: comparison with 3H-Di]nydromophine and 3H-Naloxone. Res. Commun. Chem. Pathol. Pharmacol. 21:409, 1978.

    PubMed  CAS  Google Scholar 

  34. Besser G.M., Mc Neilly A.S., Anderson D.C., Marshall J.C., Harsoulis P., Hall R., Ormston B.J., Alexander L., Collins W.P. Hormonal responses to synthetic luteinizing hormone and follicle stimulating hormone releasing hormone in man. Br. Med. J. 3:267, 1972.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cattedra di Andrologia, V Clinica Medica, Università di Roma “La Sapienza”, Roma, Italy

    F. Fraioli,  A. Fabbri M.D., L. Gnessi, C. Moretti, V. Bonifacio & A. Isidori

  2. Molecular Endocrinology Section, NICHD, NIH, Bethesda, MD, 20205, USA

    M. Dufau

  3. V Clinica Medica, Policllinico Umberto I, Università di Roma, 00161, Roma, Italy

    F. Fraioli

Authors
  1. F. Fraioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Fabbri M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Gnessi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Moretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Bonifacio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Isidori
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Dufau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fraioli, F., Fabbri, A., Gnessi, L. et al. Naloxone increases bioactive LH in man: evidence for selective release of early LH pool. J Endocrinol Invest 8, 513–517 (1985). https://doi.org/10.1007/BF03348550

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03348550

Key-words

Search

Navigation